Fw: Ref.: (LML) American Leprosy Missions: First Leprosy-Specific Vaccine Progresses to Phase 1b Human Trials

 

 

Leprosy Mailing List – October 23,  2024

 

Ref.:  (LML) American Leprosy Missions: First Leprosy-Specific Vaccine Progresses to Phase 1b Human Trials

From:  Jessica Mussro, Greenville, USA

---

 

 

Dear Dr. Schreuder and colleagues,

 

I'm reaching out to announce that American Leprosy Missions (ALM) is initiating the Phase 1b clinical trials of LepVax: the world's first leprosy-specific vaccine! Five years after completing Phase 1a trials in the U.S., Phase 1b will take place in Brazil, a leprosy-endemic area. 

 

Every two minutes someone is diagnosed with leprosy, while four million people live with the lifelong disabilities and social stigma caused by this marginalizing disease. However, recent models show that if LepVax is released between 2028 and 2040, we can interrupt transmission and prevent 823,000 new cases of leprosy-related disability. We are seizing this historic opportunity to help end leprosy and leave a lasting legacy for millions of people worldwide!

 

These are the links to ALM's press release and additional media resources. Please contact me with any questions or requests for interviews with our staff. 

 

Best regards,

 

Jessica Mussro 

Communications Manager

 

AMERICAN LEPROSY MISSIONS

One ALM Way, Greenville, South Carolina 29601 

jmussro@leprosy.org | leprosy.org 

---

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/f30e7ae2-a1ea-4b6e-bd3a-8b257c11e289n%40googlegroups.com.